RECRUITING

iCCaRE Consortium Pilot Project 1: Feasibility of a Point of Prostate Cancer Diagnosis Intervention for Newly Diagnosed Black Men

Conditions

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This study is being done to determine the acceptance and effectiveness of a virtual robot assistant model at a urology clinic.

Official Title

iCCaRE Consortium Pilot Project 1: Feasibility of a Point of Prostate Cancer Diagnosis Intervention for Newly Diagnosed Black Men

Quick Facts

Study Start:2023-11-20

Study Completion:2026-12-01

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:RECRUITING

Study ID

NCT06535802

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:Not specified to 80 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:Yes

Standard Ages:CHILD, ADULT, OLDER_ADULT

Inclusion Criteria	Exclusion Criteria
* AIM 1: iCCaRE Consortium consumer advocates, clinicians as part of the iCCaRE Consortium Translational Research \& Clinical Intervention Services core, and non-iCCaRE affiliated member. * AIM 2 ALPHA TESTING: 1 representative from each of the other iCCaRE five projects and six cores/services and 1 non iCCaRE affiliated member * AIM 2 BETA TESTING-PATIENTS: * A Black male * A patient who has been diagnosed with prostate cancer in Florida * Have an abnormal PSA and/or DRE lab value within the previous 6 months * Minimum age of 30 yrs * Consent to participating in the intervention	* AIM 2 BETA TESTING-PATIENTS: * Patients who are not Black males * Not patients at a urology clinic * Have normal PSA and/or DRE lab values within the previous 6 months * Older than 80 yrs * Are not willing to consent

Inclusion Criteria

Exclusion Criteria

* AIM 1: iCCaRE Consortium consumer advocates, clinicians as part of the iCCaRE Consortium Translational Research \& Clinical Intervention Services core, and non-iCCaRE affiliated member.
* AIM 2 ALPHA TESTING: 1 representative from each of the other iCCaRE five projects and six cores/services and 1 non iCCaRE affiliated member
* AIM 2 BETA TESTING-PATIENTS:
* A Black male
* A patient who has been diagnosed with prostate cancer in Florida
* Have an abnormal PSA and/or DRE lab value within the previous 6 months
* Minimum age of 30 yrs
* Consent to participating in the intervention

* AIM 2 BETA TESTING-PATIENTS:
* Patients who are not Black males
* Not patients at a urology clinic
* Have normal PSA and/or DRE lab values within the previous 6 months
* Older than 80 yrs
* Are not willing to consent

Contacts and Locations

Principal Investigator

Folakemi T. Odedina, PhD

PRINCIPAL_INVESTIGATOR

Mayo Clinic

Study Locations (Sites)

Mayo Clinic in Florida

Jacksonville, Florida, 32224-9980

United States

Collaborators and Investigators

Sponsor: Mayo Clinic

Folakemi T. Odedina, PhD, PRINCIPAL_INVESTIGATOR, Mayo Clinic

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2023-11-20

Study Completion Date2026-12-01

Study Record Updates

Study Start Date2023-11-20

Study Completion Date2026-12-01

Terms related to this study

Additional Relevant MeSH Terms

Prostate Carcinoma